JOJulian O. M. Ormerod

Julian O. M. Ormerod

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julian O. M. Ormerod has a total of 369 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and Feasibility of Magnetic Resonance Imaging Within the First Week Following Transvenous Pacing System Implantation

    by Jonathan Raby, Benjamin Bussmann, Pok-Tin Tang, C. Fielder Camm, Dimitrios Panagopoulos, Hongyan Tao, Jennifer J. Rayner, Timothy R. Betts, Matthew Ginks, Julian Ormerod, et al.

  • Open Access

    Successful implantation of an extravascular implantable cardioverter-defibrillator in a patient with moderate pectus excavatum: a case report

    by Holden Eaton, Hesham Aggour, Julian O M Ormerod

    Background: Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death due to ventricular arrhythmia. A novel extravascular ICD (EV-ICD) system provides improved functionality over previous transvenous (TV-ICD) and subcutaneous (S-ICD) alternatives, particularly in younger patients. This includes limited bradycardia pacing, anti-tachycardia pacing therapy, and lower energy defibrillation, all within a smaller device profile compared to the S-ICD. Due to the need for substernal lead placement, however, complex sternal anatomy is currently considered a relative contraindication to their use. Case summary: We present a 38-year-old male patient with pectus excavatum and a previous episode of ventricular fibrillation leading to out-of-hospital cardiac arrest. Initial implantation of a S-ICD was associated with repeated inappropriate shocks over 4 years, leading to multidisciplinary discussions with the patient regarding off-label use of an EV-ICD, as approved by Medtronic CRM. Explantation of the S-ICD and implantation of the EV-ICD were successful, with minimal technical changes required compared to standard surgical technique in normal sternal anatomy. At 6-month follow-up, there were no complications or inappropriate shocks. Discussion: The EV-ICD may be considered in patients with pectus excavatum, making this novel device available to a larger proportion of patients. Aside from careful consideration of instrument positioning during the procedure, this can be done with minimal changes to the standard surgical protocol.


  • Combined RNA Splicing and Patch-Clamp Analysis Reveal Pathogenicity of Splice-Altering Variants in KCNH2 -Related LQTS

    by Susan Clasper, Gunjan Trivedi, Kate L. Thomson, Claire L.S. Turner, Smrithi Devaiah, Catherine L. Mercer, Amnah Y. Bdeir, Jumana Y. Al-Aama, Khalid Dagriri, Alex R. Hobson, et al.


  • Open Access

    Ventricular Conduction Stability Noninvasively Identifies an Arrhythmic Substrate in Survivors of Idiopathic Ventricular Fibrillation

    by Ji‐Jian Chow, Kevin M. W. Leong, Matthew J. Shun‐Shin, Julian O. M. Ormerod, Michael Koa‐Wing, David C. Lefroy, Phang Boon Lim, Nicholas W. F. Linton, Fu Siong Ng, Norman A. Qureshi, et al.

    Background: Idiopathic ventricular fibrillation (VF) is a diagnosis of exclusion following normal cardiac investigations. We sought to determine if exercise‐induced changes in electrical substrate could distinguish patient groups with various ventricular arrhythmic pathophysiological conditions and identify patients susceptible to VF. Methods and Results: Computed tomography and exercise testing in patients wearing a 252‐electrode vest were combined to determine ventricular conduction stability between rest and peak exercise, as previously described. Using ventricular conduction stability, conduction heterogeneity in idiopathic VF survivors (n=14) was compared with those surviving VF during acute ischemia with preserved ventricular function following full revascularization (n=10), patients with benign ventricular ectopy (n=11), and patients with normal hearts, no arrhythmic history, and negative Ajmaline challenge during Brugada family screening (Brugada syndrome relatives; n=11). Activation patterns in normal subjects (Brugada syndrome relatives) are preserved following exercise, with mean ventricular conduction stability of 99.2±0.9%. Increased heterogeneity of activation occurred in the idiopathic VF survivors (ventricular conduction stability: 96.9±2.3%) compared with the other groups combined (versus 98.8±1.6%; P =0.001). All groups demonstrated periodic variation in activation heterogeneity (frequency, 0.3–1 Hz), but magnitude was greater in idiopathic VF survivors than Brugada syndrome relatives or patients with ventricular ectopy (7.6±4.1%, 2.9±2.9%, and 2.8±1.2%, respectively). The cause of this periodicity is unknown and was not replicable by introducing exercise‐induced noise at comparable frequencies. Conclusions: In normal subjects, ventricular activation patterns change little with exercise. In contrast, patients with susceptibility to VF experience activation heterogeneity following exercise that requires further investigation as a testable manifestation of underlying myocardial abnormalities otherwise silent during routine testing.

  • PO-648-02 INCIDENCE OF FALSE-POSITIVE AF DETECTION WITH THE NEW CONFIRM RX™ WITH SHARP-SENSE TECHNOLOGY IN ‘REAL-WORLD’ PATIENTS

    by Andre Rodrigues Pontes Briosa e Gala, Michael Tb Pope, Milena Leo, Julian O.M. Ormerod, Honey Thomas, Mark M. Gallagher, Roy S. Gardner, Duncan C. Field, David Wilson, Ross J. Hunter, et al.

  • PO-648-01 DIAGNOSTIC PERFORMANCE OF THE CONFIRM RX WITH SHARPSENSE TECHNOLOGY FOR AF EPISODES OF DIFFERENT DURATION: UK EXPERIENCE

    by Andre Rodrigues Pontes Briosa e Gala, Michael Tb Pope, Milena Leo, Julian O.M. Ormerod, Honey Thomas, Mark M. Gallagher, Ross J. Hunter, Duncan C. Field, David Wilson, Roy S. Gardner, et al.

  • Open Access

    Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome

    by Julian O.M. Ormerod, Elizabeth Ormondroyd, Yanhui Li, John Taylor, Jinhong Wei, Wenting Guo, Ruiwu Wang, Caroline N.S. Sarton, Karen McGuire, Helene M.P. Dreau, et al.

    Background: A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described. We evaluated a large and well characterized family to assess provocation testing, risk factor stratification and response to therapy in CRDS. Methods: We present a family with multiple unheralded sudden cardiac deaths and aborted cardiac arrests, primarily in children and young adults, with no clear phenotype on standard clinical testing. Results: Genetic analysis, including whole genome sequencing, firmly established that a missense mutation in RYR2 , Ala4142Thr, was the underlying cause of disease in the family. Functional study of the variant in a cell model showed RyR2 loss-of-function, indicating that the family was affected by CRDS. EPS (Electrophysiological Study) was undertaken in 9 subjects known to carry the mutation, including a survivor of aborted sudden cardiac death, and the effects of flecainide alone and in combination with metoprolol were tested. There was a clear gradation in inducibility of nonsustained and sustained ventricular arrhythmia between subjects at EPS, with the survivor of aborted sudden cardiac death being the most inducible subject. Administration of flecainide substantially reduced arrhythmia inducibility in this subject and abolished arrhythmia in all others. Finally, the effects of additional metoprolol were tested; it increased inducibility in 4/9 subjects. Conclusions: The Ala4142Thr mutation of RYR2 causes the novel heritable arrhythmia syndrome CRDS, which is characterized by familial sudden death in the absence of prior symptoms or a recognizable phenotype on ambulatory monitoring or exercise stress testing. We increase the experience of a specific EPS protocol in human subjects and show that it is helpful in establishing the clinical status of gene carriers, with potential utility for risk stratification. Our data provide evidence that flecainide is protective in human subjects with CRDS, consistent with the effect previously shown in a mouse model.


  • Open Access

    Swimming-induced pulmonary edema: current perspectives

    by Ralph Smith, Julian O M Ormerod, Nikant Sabharwal, Courtney Kipps

    With the growing popularity of water-based sports, cases of swimming-induced pulmonary edema (SIPE) are becoming increasingly recognized. SIPE, a potentially life-threatening condition, is an acute cause of breathlessness in athletes. It has been described frequently in scuba divers, swimmers, and triathletes and is characterized by symptoms and signs of pulmonary edema following water immersion. It is important to recognize that athletes’ symptoms can present with a spectrum of severity from mild breathlessness to severe dyspnea, hemoptysis, and hypoxia. In most cases, there is rapid resolution of symptoms within 48 hours of exiting the water. Recent advances in the understanding of the pathophysiology of SIPE, particularly regarding exaggerated pulmonary vascular pressures, have begun to explain this elusive condition more clearly and to distinguish its predisposing factors. It is essential that event organizers and athletes are aware of SIPE. Prompt recognition is required not only to prevent drowning, but also to implement appropriate medical management and subsequent advice regarding return to swimming and the risk of recurrence. This manuscript provides a current perspective on SIPE regarding the incidence rate, the current understanding of the pathophysiology, clinical presentation, medical management, recurrence rates, and advice on return to sport.


  • How should I treat a patient with giant left main coronary artery aneurysm without associated stenosis?

    by Julian O.M. Ormerod, Joanna Lim, Badri Chandrasekaran, Steve Ramcharitar, Scot Garg, Ravi Singh, John McDonald, Kanarath Balachandran, Joanna J. Wykrzykowska

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Open Access

    Massive vegetation in device-related endocarditis

    by Julian O.M. Ormerod, Amar Keiralla, Raman Uberoi, Timothy R. Betts

    A 71-year-old man was transferred to the extraction centre with Staphylococcus aureus endocarditis and a 3.5 × 1.7 cm vegetation adherent to the ventricular lead of his 7-year-old secondary-prevention dual chamber ICD (see Panel A and Supplementary material online, Videos S1–S3 ). He had been initially managed medically but the vegetation increased in size. He was refused surgical extraction due to frailty and multiple co-morbidities (severe LV dysfunction, cachexia, previous hypoxic brain injury, and chronic pulmonary disease). Although the potential haemodynamic and infective consequences of embolization of the vegetation were a contraindication to percutaneous extraction, his deteriorating condition justified this novel approach. Initially, unsuccessful attempts were made to capture the vegetation with several types of snare. The leads were then extracted using a locking stylet and laser sheath and the vegetation, having briefly adhered to the tricuspid valve, disappeared from transoesophageal echo view. Pulmonary angiography located it in the origin of the left lower pulmonary artery (Panel B). It was captured with a tri-snare (Panel C) and pulled back into the IVC. The right iliac vein diameter was too small to pull it further with the snare. A 14 mm Cobra balloon was tracked beyond the vegetation and inflated. This was used alongside the snare to pull the compressed mass into the femoral vein without further embolisation, where it was removed in three pieces by open venotomy (Panel D). The patient was extubated the same day, made a full recovery and eventually discharged home.